ADC Therapeutics SA
NYSE:ADCT

Watchlist Manager
ADC Therapeutics SA Logo
ADC Therapeutics SA
NYSE:ADCT
Watchlist
Price: 1.83 USD 4.57%
Market Cap: 176.9m USD

Gross Margin
ADC Therapeutics SA

94.2%
Current
97%
Average
63.5%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
94.2%
=
Gross Profit
116.4m
/
Revenue
123.5m

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
CH
ADC Therapeutics SA
NYSE:ADCT
176.9m USD
94%
FR
Pharnext SCA
OTC:PNEXF
6T USD
0%
US
Abbvie Inc
NYSE:ABBV
303.2B USD
67%
US
Amgen Inc
NASDAQ:AMGN
146.3B USD
60%
US
Gilead Sciences Inc
NASDAQ:GILD
114.4B USD
78%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
108.8B USD
86%
US
Epizyme Inc
F:EPE
94.1B EUR
76%
AU
CSL Ltd
ASX:CSL
132.7B AUD
52%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
75B USD
87%
US
Seagen Inc
F:SGT
39.3B EUR
75%
NL
argenx SE
XBRU:ARGX
38.1B EUR
89%

ADC Therapeutics SA
Glance View

Market Cap
176.9m USD
Industry
Biotechnology

ADC Therapeutics SA is a clinical-stage biotechnology company. The company is headquartered in Epalinges, Vaud and currently employs 312 full-time employees. The company develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. The company employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The firm has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. The company serves customers in the United States, Switzerland, and the United Kingdom.

ADCT Intrinsic Value
4.91 USD
Undervaluation 63%
Intrinsic Value
Price
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
94.2%
=
Gross Profit
116.4m
/
Revenue
123.5m
What is the Gross Margin of ADC Therapeutics SA?

Based on ADC Therapeutics SA's most recent financial statements, the company has Gross Margin of 94.2%.

Back to Top